Natera

Director, Clinical and Translational Development

United States

Natera Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, Medical ResearchIndustries

Requirements

Candidates should possess an advanced degree, such as a Ph.D., MD, or PharmD, in life sciences, biology, pharmacology, or a related discipline, and a minimum of 10 years of relevant industry experience in clinical and/or pre-clinical drug development. They should have in-depth knowledge of clinical trial design, execution, regulatory requirements, and compliance standards, along with experience interacting directly with regulatory bodies like the FDA and EMA and preparing regulatory documentation.

Responsibilities

The Director, Clinical and Translational Development will lead the planning, execution, and oversight of clinical trials and pre-clinical research programs, ensuring alignment with strategic objectives and regulatory requirements. They will design and oversee clinical trial protocols, collaborate with biostatisticians, develop critical clinical documents, and deliver presentations to stakeholders. This role involves overseeing clinical trial management, ensuring compliance with regulatory standards, managing budgets and timelines, mentoring a team, and collaborating with cross-functional teams including R&D, Regulatory, Medical Affairs, and CROs. Furthermore, they will develop and implement clinical and pre-clinical development strategies, oversee regulatory submissions such as INDs and CTAs, and manage interactions with regulatory agencies.

Skills

Clinical Trials Management
Pre-clinical Research
Regulatory Compliance
Clinical Trial Protocol Design
Data Analysis
Biostatistics
Regulatory Pathways
Stakeholder Communication
Cross-functional Collaboration
Clinical Development Strategy

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Key Metrics

Austin, TexasHeadquarters
2004Year Founded
$149.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Flexible medical plans
Investment options
Time off
Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
New Prospera Heart features may face slow adoption by healthcare providers.
Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
AI integration enhances accuracy and speed of Natera's cfDNA analysis.
Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI